Premium
Ant venom immunotherapy in Australia: the unmet need
Author(s) -
Mullins Raymond J,
Brown Simon G A
Publication year - 2014
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/mja13.00035
Subject(s) - venom , anaphylaxis , tolerability , allergy , medicine , immunotherapy , immunology , bee venom , biology , pharmacology , ecology , adverse effect , zoology , immune system
Summary Jack jumper ant (JJA) venom allergy is an important cause of anaphylaxis in south‐eastern Australia. The efficacy and real‐world effectiveness of JJA venom immunotherapy (VIT) to prevent anaphylaxis in allergic patients are now well established, with an evidence base that is at least equivalent to that supporting VIT for allergy to other insect species. The tolerability and safety of JJA VIT are comparable with those of honeybee VIT.